Inactive Instrument
IRLAB Therapeutics AB Share Price Nasdaq Stockholm
Stocks
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Nasdaq Stockholm
|
||
| - SEK | - |
|
| 27/10 | Irlab Therapeutics Set to Obtain US Patent for Parkinson's Disease Drug Candidate | MT |
| 27/10 | Irlab receives positive patent notice in the US for IRL1117 | FW |
| Market Cap | 31Cr 3.16Cr 2.83Cr 2.61Cr 2.36Cr 4.41Cr 300.4Cr 4.5Cr 12Cr 158.02Cr 12Cr 12Cr 498.33Cr | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 31Cr 3.16Cr 2.83Cr 2.61Cr 2.36Cr 4.41Cr 300.4Cr 4.5Cr 12Cr 158.02Cr 12Cr 12Cr 498.33Cr | EV / Sales 2026 * |
3.07x | EV / Sales 2027 * | 2.17x |
| Free-Float |
83.4% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 01/08/2024 | |
Susanna Waters
PRN | Corporate Officer/Principal | 60 | 01/01/2013 |
Clas Sonesson
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/01/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Rein Piir
BRD | Director/Board Member | 68 | 01/01/2016 |
| Chairman | 73 | 07/05/2020 | |
Veronica Wallin
BRD | Director/Board Member | 40 | 01/01/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.19% | +11.31% | +64.28% | +155.66% | 1,26300Cr | |
| -0.73% | +3.56% | +44.65% | +83.74% | 66TCr | |
| +1.41% | +3.24% | +35.25% | +106.98% | 52TCr | |
| -1.59% | +0.10% | +52.95% | +66.66% | 39TCr | |
| +2.18% | +2.93% | +73.90% | +45.38% | 37TCr | |
| -1.54% | +3.07% | +32.06% | +55.21% | 31TCr | |
| -1.56% | +7.03% | +11.27% | +32.77% | 29TCr | |
| +1.15% | +6.09% | +56.15% | +78.66% | 25TCr | |
| +3.06% | +9.38% | +42.48% | +112.84% | 21TCr | |
| Average | -0.50% | +5.90% | +45.89% | +81.99% | 47.35TCr | |
| Weighted average by Cap. | -0.62% | +6.60% | +50.01% | +98.62% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10Cr 1.03Cr 92.26L 84.86L 76.89L 1.44Cr 98Cr 1.46Cr 4.06Cr 51Cr 3.87Cr 3.78Cr 162.26Cr | 14Cr 1.46Cr 1.31Cr 1.2Cr 1.09Cr 2.03Cr 138.4Cr 2.07Cr 5.75Cr 73Cr 5.47Cr 5.35Cr 229.6Cr |
| Net income | -3.61Cr -36.75L -32.91L -30.27L -27.43L -51.27L -35Cr -52.23L -1.45Cr -18Cr -1.38Cr -1.35Cr -58Cr | 3.46Cr 35.22L 31.54L 29.01L 26.29L 49.14L 33Cr 50.06L 1.39Cr 18Cr 1.32Cr 1.29Cr 55Cr |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Calendar
Select your edition
All financial news and data tailored to specific country editions
